Latest News and Press Releases
Want to stay updated on the latest news?
-
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American...
-
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
-
JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
-
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
-
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
-
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
-
미국 플로리다주 주피터, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 글로벌 바이오테크 기업인 Dyadic International, Inc. (NASDAQ: DYAI)은 Johnson & Johnson 산하 Janssen Pharmaceutical Companies에 소속된 Janssen Biotech, Inc.와 연구,...
-
フロリダ州ジュピタ, Dec. 18, 2021 (GLOBE NEWSWIRE) -- ダイアディック･インターナショナル (Dyadic International, Inc.、以下「ダイアディック」、「同社」) (NASDAQ: DYAI)...
-
佛罗里达州朱庇特, Dec. 18, 2021 (GLOBE NEWSWIRE) -- 专注于进一步创新、应用和部署其专有C1细胞蛋白质生产平台以针对蛋白质疫苗和疗法加速开发、降低生产成本和提高性能的全球生物技术公司Dyadic International, Inc.（以下简称为“Dyadic”、“我们”、“我们的”或“公司”）（纳斯达克股票代码：DYAI）宣布，公司已与强生（Johnson...
-
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...